JPRN-UMIN000006144
Completed
Phase 2
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the Lung - A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the Lung
Central Japan Lung Study Group0 sites32 target enrollmentAugust 12, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Central Japan Lung Study Group
- Enrollment
- 32
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Concomitant serious medical conditions 2\) Interstitial lung disease or pulmonary fibrosis detected by conventional computed tomography of the chest 3\) Massive pleural or pericardial effusion or ascites that required drainage, superior vena caval syndrome or symptomatic brain metastasis 4\) History of serious drug allergy 5\) Previous radiotherapy to the primary tumor 6\) Other concurrent active malignancy 7\) Pregnancy or lactation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
Completed
Not Applicable
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20
Unknown
Not Applicable
A Phase II Trial of Gefitinib Monotherapy in Elderly Chemo-naïve Patients with Advanced Non–Small Cell Lung Canceron small cell lung cancerJPRN-C000000118OGIK60
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Recruiting
Not Applicable
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplificatioKCT0004066Samsung Medical Center3